Novel, Targeted Therapies
With our scientific collaborators and advisors, we are leaders in the scientific areas underpinning our two investigational clinical product candidates: zilovertamab, an anti-ROR1 antibody, and ONCT-216, a small molecule ETS-family transcription factor inhibitor. In addition, we have preclinical programs that include a ROR1-targeting cell therapy program for hematologic and solid malignancies, and a dual-action androgen receptor inhibitor (DAARI) program for advanced prostate cancer resistant to available therapies.
Each of our product candidates is made to attack very specific mechanisms that cancer cells use to grow, thrive and metastasize. Each of our product candidates is designed to target these oncogenic pathways in cancer cells, while minimally affecting normal tissues and organs.
With our drug development expertise and a strong network of academic collaborations, we are uniquely positioned to turn these important research discoveries into new potential therapies for patients with cancers with critical unmet patient need.